iBio, Inc.
About iBio, Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $400.0K
- Net income
- -$18.4M
- Total assets
- $23.2M
- Market cap
- $90.4M
- Operating margin
- -4650.5%
- Net margin
- -4594.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $400.0K
- Operating expenses
- $19.0M
- Operating income
- -$18.6M
- Income tax
- -$8.5M
- Net income
- -$18.4M
- EPS (basic)
- $-1.75
- EPS (diluted)
- $-1.75
Balance sheet
- Total assets
- $23.2M
- Current assets
- $9.7M
- Total liabilities
- $8.3M
- Current liabilities
- $6.1M
- Shareholders’ equity
- $14.9M
Cash flow
- Operating cash flow
- -$15.3M
- Investing cash flow
- $742.0K
- Financing cash flow
- $8.9M
- Net cash flow
- -$5.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $90.4M
- EPS (diluted)
- $-1.75
- Shares outstanding
- 52.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 19, 2008
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $18.4M in FY2025.
- Revenue declined 83% from FY2021 to FY2025.
- Trading 44% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review iBio, Inc..
Write a review
News about iBio, Inc.
News & sentiment via Polygon.io
